Some aspects of the intellectual property legislation development to expand access to biotechnology medicines

The article examines the legal aspects of intellectual property and their impact on access to biotechnology medicines, considering prospects for legislative reform. The author analyzes legal mechanisms for ensuring access to medicines and their implementation in national legislation. Key priorities and reform prospects in intellectual property and pharmaceutical legislation are identified, addressing the challenges of martial law, European integration commitments, and the need to eliminate barriers to the timely market entry of generics and biosimilars. Intellectual property rights are a valuable asset of companies developing biotechnology products, and proper protection of intellectual property rights provides incentives for research in the pharmaceutical industry. Ukraine remains an importer of certain biotechnology products, including innovative medicines and vaccines not produced domestically. However, the country possesses well-developed manufacturing facilities capable of supplying high-quality generics and biosimilars to the domestic market. Efforts are underway to harmonize national legislation with EU law. Currently, there is no comprehensive legislative approach to regulating the use of biotechnology methods. Given ongoing transformations in EU pharmaceutical and biotechnology legislation, similar changes are expected in Ukraine. At the same time, a clear and unified conceptual framework remains necessary. Amid Russia’s military aggression, ensuring access to innovative medicines for the treatment of incurable or difficult-to-treat diseases is of critical importance. To expand access to biotechnology products, attract investment in the pharmaceutical industry and the introduction of innovations, and stabilize the market — particularly for generics, which are well-developed in Ukraine — legislative changes should enhance the effectiveness of the compulsory licensing mechanism. Strengthening this mechanism would serve as a vital tool for responding to emergencies and crises while safeguarding national economic interests

Authors

Institutions

Publication Details

Journal
Theory and Practice of Intellectual Property
Published
2025-03-18
DOI
https://doi.org/10.33731/12025.325004
Primary Topic
Biotechnology and Related Fields
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Some aspects of the intellectual property legislation development to expand access to biotechnology medicines

Olha Omelchenko
Theory and Practice of Intellectual Property
Biotechnology and Related Fields
article

Some aspects of the intellectual property legislation development to expand access to biotechnology medicines

Olha Omelchenko
article en

Abstract

The article examines the legal aspects of intellectual property and their impact on access to biotechnology medicines, considering prospects for legislative reform. The author analyzes legal mechanisms for ensuring access to medicines and their implementation in national legislation. Key priorities and reform prospects in intellectual property and pharmaceutical legislation are identified, addressing the challenges of martial law, European integration commitments, and the need to eliminate barriers to the timely market entry of generics and biosimilars. Intellectual property rights are a valuable asset of companies developing biotechnology products, and proper protection of intellectual property rights provides incentives for research in the pharmaceutical industry. Ukraine remains an importer of certain biotechnology products, including innovative medicines and vaccines not produced domestically. However, the country possesses well-developed manufacturing facilities capable of supplying high-quality generics and biosimilars to the domestic market. Efforts are underway to harmonize national legislation with EU law. Currently, there is no comprehensive legislative approach to regulating the use of biotechnology methods. Given ongoing transformations in EU pharmaceutical and biotechnology legislation, similar changes are expected in Ukraine. At the same time, a clear and unified conceptual framework remains necessary. Amid Russia’s military aggression, ensuring access to innovative medicines for the treatment of incurable or difficult-to-treat diseases is of critical importance. To expand access to biotechnology products, attract investment in the pharmaceutical industry and the introduction of innovations, and stabilize the market — particularly for generics, which are well-developed in Ukraine — legislative changes should enhance the effectiveness of the compulsory licensing mechanism. Strengthening this mechanism would serve as a vital tool for responding to emergencies and crises while safeguarding national economic interests

Theory and Practice of Intellectual Property(1)
Human Growth Foundation (US)
Openalex Percentile: Top 93%
Biotechnology and Related Fields
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Some aspects of the intellectual property legislation development to expand access to biotechnology medicines — Olha Omelchenko · Theory and Practice of Intellectual Property (2025) | TGRS Research Map | TGRS